A deeper understanding of the multifaceted roles of monocytes and macrophages in IIM pathogenesis is paving the way for ... mesenchymal stem cell-derived exosomes (MSC-Exos), JAK inhibitors, ...

Patients on anifrolumab spent more time in remission and low disease activity, and reached those states more quickly, vs. placebo. Achieving these states can stave off permanent organ damage.

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...

So, that's exciting news. The anifrolumab trial is moving along nicely. And so we might know soon, whether or not we might have an anti-interferon agent available for the treatment of lupus nephritis.

Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

The amelioration of the B cell immunity signature across diverse treatments emphasises the key role of B cells in the pathogenesis of SLE through autoantibody production and antibody-independent ...

Objective We herein describe the current state of stricture pathogenesis, measuring tools and clinical trial endpoints development. Design Data presented and discussed in this review derive from the ...

Int J Clin Rheumatol. 2010;5(4):407-413.

Impact and progress Frontiers' impact All annual reports Annual report 2024 ...